Search
for
Sort by
Research 571–600 of 1000+
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
- BH14 Multiple sclerosis and alopecia areata: drug-induced alopecia areata or coexisting autoimmune phenomena?
- Guidelines for the management of alopecia areata
- A novel therapeutic paradigm for patients with extensive alopecia areata
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- Alopecia Areata
- Homoeopathic management of alopecia areata barbae with Kali carbonicum: A case report
- MOST IMPORTANT SKIN DISEASES OF CHILDRENTheir Diagnosis and Treatment
- Anticytokine therapy, particularly anti-IFN-γ, in Th1-mediated autoimmune diseases
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Alopecia Areata Update
- Advances in the management of alopecia areata
- Alopecia Areata
- Alopecia areata: An update
- New drugs under investigation for the treatment of alopecias
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
- Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
- A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
- Diphenylcyclopropenone in severe alopecia areata in children and adolescents: long-term follow-up and relapse rate
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
- METROPOLITAN DERMATOLOGICAL SOCIETY OF NEW YORK
- Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor